We describe clonal shifts in \textit{vanA Enterococcus faecium} isolates from clinical samples obtained from patients in Denmark from 2015 to the first quarter (Q1) of 2019. During Q1 2019, the \textit{vancomycin-variable enterococci} (VVE) \textit{ST1421-CT1134} clone, Denmark, 2015 to March 2019. Euro Surveill. 2019;24(34):pii=1900503. https://doi.org/10.2807/1560-7917.ES.2019.24.34.1900503

We describe clonal shifts in \textit{vanA Enterococcus faecium} isolates from clinical samples obtained from patients in Denmark from 2015 to the first quarter (Q1) of 2019. During Q1 2019, the \textit{vancomycin-variable enterococci} (VVE) \textit{ST1421-CT1134} clone, Denmark, 2015 to March 2019. Euro Surveill. 2019;24(34):pii=1900503. https://doi.org/10.2807/1560-7917.ES.2019.24.34.1900503

\textbf{Rapid Communication}

\textbf{Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable \textit{vanA Enterococcus faecium} \textit{ST1421-CT1134} clone, Denmark, 2015 to March 2019}

Anette M Hammerum\(^1\), Ulrik S Justesen\(^2\), Mette Pinholt\(^3\), Louise Roer\(^4\), Hülya Kaya\(^5\), Peder Worning\(^6\), Sanne Nygaard\(^7\), Michael Kemp\(^8\), Marianne Engeli Clausen\(^9\), Karen Leth Nielsen\(^4\), Jurgita Samulionienė\(^7\), Mona Kjærgaard\(^8\), Claus Østergaard\(^9\), John Coia\(^10\), Turid Snekleth Søndergaard\(^3\), Shahin Gaini\(^11\)\(^,\)\(^12\), Kristian Schønning\(^3\)\(^,\)\(^15\), Henrik Westh\(^10\), Henrik Hasman\(^1\), Barbara Juliane Holzknecht\(^1\)

1. Department for Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
2. Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark
3. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark
4. Department of Clinical Microbiology, Herlev and Gentofte University Hospital, Herlev, Denmark
5. Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark
6. Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark
7. Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark
8. Department of Clinical Microbiology, Lillebaelt Hospital, Vejle, Denmark
9. Department of Clinical Microbiology, Hospital Sønderjylland, Sønderborg, Denmark
10. Department of Clinical Microbiology, Hospital South West Jutland, Esbjerg, Denmark
11. Department of Clinical Microbiology, Hospital Sønderjylland, Sønderborg, Denmark
12. Medical Department, National Hospital Faroe Islands, Torshavn, Faroe Islands
13. Centre of Health Research, University of the Faroe Islands, Torshavn, Faroe Islands
14. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Correspondence: Anette M Hammerum (ama@ssi.dk)

\textbf{Citation style for this article:}


\textbf{We describe clonal shifts in \textit{vanA Enterococcus faecium} isolates from clinical samples obtained from patients in Denmark from 2015 to the first quarter (Q1) of 2019. During Q1 2019, the \textit{vancomycin-variable enterococci} (VVE) \textit{ST1421-CT1134} clone, Denmark, 2015 to March 2019. Euro Surveill. 2019;24(34):pii=1900503. https://doi.org/10.2807/1560-7917.ES.2019.24.34.1900503}

We describe the clonal shift for \textit{vanA Enterococcus faecium} during the last 4 years and the national spread of a \textit{vancomycin-variable Enterococcus faecium} \textit{ST1421-CT1134} clone in Denmark. The aim is to highlight the importance of using molecular methods for detecting \textit{vancomycin-variable enterococci} (VVE), and to alert other countries about this emerging nosocomial clone.

\textbf{Vancomycin-variable enterococci}

Vancomycin-variable enterococci (VVE) are \textit{E. faecium} harboring the \textit{vanA} gene complex, but being phenotypically vancomycin susceptible [1,2]. VVE can only be detected by molecular methods and cannot be cultured on selective vancomycin-containing media. Different clones of VVE have caused nosocomial outbreaks and development of vancomycin-resistant revertant mutants \textit{in vitro} and \textit{in vivo} has been described [1,3-5]. This makes the detection of VVE highly important in clinical samples in order to assure relevant antibiotic treatment and in screening samples to avoid nosocomial spread. In 2015 and 2016, sporadic VVE with different genetic background were detected in the Capital Region of Denmark, in connection with vancomycin-resistant enterococci (VRE) outbreaks (data not shown). In 2016, a VVE clone belonging to \textit{ST1421-CT1134}, which displays variable vancomycin susceptibility (minimum inhibitory concentration (MIC) 1 \text{to} 256 \text{mg/ml}) was detected in screening samples from a hospital in the Capital Region [5]. One strain, Efm-V1511, belonging to this clone was characterised by Hansen et al. [5]. Efm-V1511 had a 49.6 Kp plasmid, which carried the \textit{Tn}1546 (\textit{vanA} transposon). \textit{Tn}1546 was truncated in \textit{vanX} by a 252 bp 3' deletion explaining the vancomycin susceptibility of Efm-V1511. In \textit{ST1421-CT1134} isolates resistant to vancomycin, resistance could be attributed to changes in \textit{ddl} disrupting
**Figure 1**
The five healthcare regions and the 10 Departments of Clinical Microbiology, Denmark, 2019

Modified from DANMAP 2017 [7].

DCM: Department of Clinical Microbiology; ND: not detected.

Gene function sometimes accompanied by changes in vanS, increased pHVH-V1511 copy number or the existence of an additional vanA-containing plasmid encoding a functional vanX [5].

National surveillance of vancomycin-resistant and vancomycin-variable enterococci

We have previously described the surveillance of vancomycin-resistant enterococci (VRE) in clinical isolates in Denmark from 2005 to 2015 [6]. In the present study, we follow up and describe the data from isolates obtained from 2016 through the first quarter (Q1) of 2019. Since 2005, VRE isolates from clinical samples, e.g. urine, blood and tissue, as opposed to screening (faecal) isolates have been voluntarily submitted to Statens Serum Institut (SSI) from Danish Departments of Clinical Microbiology (DCM) for species identification, genotyping and surveillance (Figure 1) [7]. Only one isolate per patient per 12 months was included. All VRE isolates (699 *E. faecium* and 30 *E. faecalis*) were tested for the presence of vancomycin resistance genes *vanA* and *vanB* by PCR from 2005 through 2014. From 2015 through Q1 2019, all clinical VRE/VVE isolates (n = 1,935) underwent whole-genome sequencing (WGS) as previously described [6]. From the WGS data, multilocus sequence type (MLST), and van genes were extracted *in silico*. The isolates were further subtyped in SeqSphere+(Ridom GmbH, Münster, Germany (http://www.ridom.de/seqsphere/)) using the cgMLST scheme by de Been et al. [8] for *E. faecium*.

VVE diagnostic algorithms have developed substantially over time and between the five Danish regions. In 2017, testing of phenotypically vancomycin-susceptible *E. faecium* isolates from blood cultures for the presence of *vanA/vanB* genes by PCR was introduced in the DCMs in the Capital Region. During 2018, this was expanded to testing of all clinical *E. faecium* isolates. During 2018, molecular testing by PCR of *E. faecium* from all clinical samples was also implemented in one of the four DCMs in the Region of Southern Denmark. Furthermore, *E. faecium* isolates from blood cultures were tested by PCR for *vanA/vanB* genes in another DCM in the Region of Southern Denmark and in the DCM in the Central Denmark Region in 2018. In Q1 2019, diagnostic algorithms to detect VVE have expanded. Most of the DCMs across Denmark test at least all blood culture *E. faecium* isolates for the presence of *vanA* genes using PCR.

**Enterococcus faecium** and **Enterococcus faecalis** isolates from clinical samples carrying *vanA* and *vanB* genes

From 2005 to Q1 2019, 2,503 *vanA* *E. faecium*, 74 *vanB* *E. faecium*, 32 *vanA/vanB* *E. faecium*, 12 *vanA* *E. faecalis*, and 43 *vanB* *E. faecalis* from clinical samples were submitted to SSI (Figure 2).

Emergence and disappearance of major **Enterococcus faecium** clones

Of the 1,935 VRE/VVE isolates obtained from 2015 through Q1 2019, 1,910 were *E. faecium* and 25 *E. faecalis* (Figure 2).

The *E. faecium* isolates belonged to 29 sequence types (STs). ST80 (22%), ST203 (65%) and ST1421 (9%) were most prevalent. Typing by cgMLST revealed 156 different complex types (CTs).

The 13 most common types of *vanA*, *vanB* and *vanA/vanB* *E. faecium* from 2015 to Q1 2019 are shown in Table 1. From 2015 to 2019, three types were dominating: ST80-CT14 *vanA E. faecium*, ST203-CT859 *vanA E. faecium* and ST1421-CT1134 *vanA E. faecium* (Table 1). In 2015, 22% of the *E. faecium* isolates belonged to ST80-CT14 *vanA E. faecium*. The type decreased during 2016.

ST203-CT859 *vanA E. faecium* isolates were first detected during the end of 2014 [6]. It emerged very fast and was the most prevalent *vanA E. faecium* type (together with its subtypes CT1051 and CT1507) during 2015 to 2017, but decreased in 2018 (Table 1). In Q1 2019 only 12% of the VRE/VVE *E. faecium* isolates belonged to ST203-CT859.

In 2017, 3% of the *E. faecium* isolates belonged to the VVE clone, ST1421-CT1134 *vanA E. faecium*. This type
was only detected from clinical samples from the Capital Region. In 2018, 34% of the *E. faecium* isolates belonged to ST1421-CT1134 and were detected in the Capital Region, the Region Zealand and from one DCM in the Region of Southern Denmark (Table 1, Table 2). During Q1 2019, ST1421-CT1134 *vanA E. faecium* was the most prevalent type (44%) (Table 1). It was detected in all five regions of Denmark, 50 isolates from the Capital Region, one isolate from Region Zealand, 23 isolates from the Region of Southern Denmark, two isolates from Central Denmark Region and one isolate from the North Denmark Region (Table 2). Furthermore, ST1421-CT1134 *vanA E. faecium* spread to the Faroe Islands during 2018 and 2019 (data not shown).

### Discussion and conclusion

During 2005 to Q1 2019, most of the Danish clinical VRE isolates have been *vanA E. faecium* isolates. This study shows that predominating clones shifted over time and, importantly, the emergence of a vancomycin-variable clone, ST1421-CT1134 *vanA E. faecium*, that has spread to all the five Danish regions in 2019.

Although the *E. faecium* isolates belonged to 156 CTs, three types (ST80-CT14 *vanA E. faecium*, ST203-CT859 *vanA E. faecium*, ST1421-CT1134 *vanA E. faecium*) have dominated during the last 4 years.

ST80-CT14 *vanA E. faecium* was highly prevalent in the Capital Region during 2012 to 2015 [9]. The *vanA E. faecium* constituting Group2_ST80 in the paper by Pinholt et al. [9] belonged to ST80-CT14 (data not shown). On a national level, the numbers of ST80-CT14 *vanA E. faecium* decreased during 2016 to 2018, and this clone was not detected during Q1 2019.

ST203-CT859 *vanA E. faecium* emerged during 2015 through 2017 and nearly disappeared 2019. This clone has spread to Sweden, the Faroe Islands and Greenland [6,7].

Because of differences in diagnostic algorithms, there is a detection bias of VVE. It seems very likely that ST1421-CT1134 *vanA E. faecium* have been under-reported in some regions at least during some periods. Thus, the rising incidence could partly be explained by...

---

**Figure 2**

Vancomycin-resistant and vancomycin-variable *Enterococcus faecium* and vancomycin-resistant *E. faecalis* isolates from clinical samples carrying van genes, Denmark, 2005–Q1 2019 (n = 2,664)
increasing molecular testing of vancomycin susceptible isolates. However, a sharply increasing incidence has also been seen in DCM with extensive testing for VVE.

The origin of ST80-CT14 vanA Enterococcus faecium and ST80-CT24 vanA are still unknown. vanA Enterococcus faecium isolates belonging to ST1421-CT1134 have also been reported from Australia, but these isolates have not been VVE [10]. Why these three clones were so successful is unknown.

The spread of the VVE clone, ST1421-CT1134 vanA Enterococcus faecium, in Denmark is of concern, especially since VVE diagnostic is challenging. Because of this, the clone is likely to be underdiagnosed, which facilitates further spread. Since cross-border spread has been described for VRE, countries with patients transferred from Denmark should be aware of the vancomycin-variable ST1421-CT1134 vanA Enterococcus faecium clone.

Acknowledgements
We thank Karin Sixhøj Pedersen and Frank Hansen for their excellent technical assistance.

Conflict of interest
None declared.

Authors' contributions
Mette Pinholt, Louise Roer, Hülya Kaya, Peder Wornin, Sanne Nygaard, Marianne Engell Clausen, Karen Leth Nielsen, Jurgita Samulioniené, Mona Kjærsgaard, Claus Østergaard, Ulrik S Justesen, John Coia, Turid Snekloth Søndergaard, Shahin Gaini, Kristian Schanning, Henrik Westh, Henrik Hasman and Barbara Holzknecht contributed to the revision of the manuscript and approved the final version. Louise Roer, Hülya Kaya, Anette M Hammerum and Henrik Hasman did the molecular analysis. Mette Pinholt, Peder Wornin, Kristian Schanning and Henrik Westh shared WGS data for many of the VRE/VVE isolates from DCM.
Hvidovre. Ulrik S Justesen, Mette Pinholt, Marianne Engell Clausen, Karen Leth Nielsen, Sanne Nygaard, Michael Kemp, Jurgita Samulioniené, Mona Kjærgaard, Claus Østergaard, John Coia, Turid Snekleth Søndergaard, Kristian Schønning, Henrik Westh and Barbara Holzknecht detected VRE/VVE at the DCMs in Denmark. Shahin Gaini shared isolates and data on the VRE/VVE from the Faroe Islands.

Anette M Hammerum and Barbara Holzknecht drafted the manuscript. Anette M Hammerum incorporated comments, additions and feedback throughout the revision.

References


License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.